Filing summary
Entity discrepancy: The request identifies Crescent BioPharma, Inc., but the supplied Form 10-Q is for GlycoMimetics, Inc. This summary reflects the filing provided, not a filing verified as belonging to Crescent BioPharma.
Business context and reporting period
Quarter ended June 30, 2015; filed August 6, 2015. GlycoMimetics is a clinical-stage biotechnology company developing glycomimetic drug candidates. It has no approved products or drug-sales revenue. Its lead candidate, rivipansel, is licensed to Pfizer; the company retains rights to its other candidates, including GMI-1271.
Financial results and liquidity
| Metric | Three months ended June 30, 2015 | Six months ended June 30, 2015 |
|---|---|---|
| Revenue | $20.04 million | $20.04 million |
| Research and development | $7.84 million | $13.05 million |
| General and administrative | $1.81 million | $3.71 million |
| Net income | $10.39 million | $3.28 million |
| Diluted earnings per share | $0.51 | $0.16 |
- Q2 operating income was $10.39 million, approximately 51.8% of revenue; six-month operating income was $3.27 million, approximately 16.3% of revenue. These results were driven by milestone revenue and should not be read as product-level operating economics.
- Cash and cash equivalents were $40.23 million at June 30, versus $55.20 million at December 31, 2014. Total current assets were $60.77 million and current liabilities $6.80 million. The filing reports no borrowings or financial debt on the balance sheet.
- Six-month operating cash flow was negative $14.85 million; investing cash flow was negative $0.21 million and financing cash flow positive $0.09 million. The operating cash outflow included a $20.0 million Pfizer milestone receivable. The company received that payment in August 2015, after quarter-end.
- Accumulated deficit was $71.12 million. The filing describes expected future operating losses and negative operating cash flows despite the reported period income.
Changes versus the prior comparable period
- Revenue increased 33% to $20.04 million in Q2 from $15.03 million in Q2 2014, reflecting a $20.0 million Pfizer milestone recognized in June 2015, compared with a $15.0 million Pfizer milestone recognized in May 2014.
- Q2 net income rose to $10.39 million from $7.99 million. For the six-month period, net income was $3.28 million versus $2.89 million.
- R&D expense increased 46% in Q2 and 41% for the first half, primarily due to GMI-1271 manufacturing/process development and clinical-trial activity. G&A expense rose 13% in Q2 and 31% year to date, mainly from public-company, professional, insurance, and compensation costs.
- Operating cash flow shifted from positive $6.63 million in the first half of 2014 to negative $14.85 million in the first half of 2015. The 2014 period included receipt of the $15.0 million Pfizer milestone; 2015’s $20.0 million milestone was not collected until August.
Outlook, risks, and notable items
- Management expected June 30 cash plus the $20.0 million Pfizer milestone received in August to fund operations and capital expenditures through Q4 2016. This is an estimate based on assumptions; the company cautioned that funds could be used sooner.
- GMI-1271’s first patient entered a Phase 1/2 AML trial in May 2015; it received FDA orphan-drug designation in May. A separate University of Michigan Phase 1 study was evaluating GMI-1271 as a potential anticoagulant. Pfizer began dosing the first patient in rivipansel’s Phase 3 trial in June 2015.
- Under the Pfizer arrangement, potential future payments include development, regulatory, and sales milestones, plus royalties; their timing and achievement are uncertain. The company owes the University of Basel 10% of specified rivipansel milestone and royalty receipts; it accrued $2.0 million related to the June milestone.
- Management expects R&D and G&A expenses to increase. Key risks include clinical-trial outcomes and timing, regulatory approval, manufacturing, intellectual-property protection, financing availability, and the possibility that candidates never become commercially viable. The company warned it may need additional capital and may be unable to obtain it on acceptable terms.
- The company moved into new Rockville headquarters in June. The eight-year lease commenced November 1, 2015, covers 33,843 square feet, and has annual base rent of $607,500 subject to escalations.
- No material legal proceedings or material changes to previously disclosed risk factors were reported. Management said disclosure controls were effective as of June 30, 2015.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is GlycoMimetics, Inc., not Crescent BioPharma, Inc.
- Check the August 2015 receipt of the $20.0 million milestone and its distinction from the June 30 receivable and cash balance.
- Assess the cash runway assumptions against clinical-trial spending, milestone uncertainty, and the stated Q4 2016 funding horizon.
- Track GMI-1271 trial progress and Pfizer’s rivipansel Phase 3 development; neither milestone revenue nor future royalties are assured.
- Review the University of Basel payment obligation and the costs of the new headquarters lease.